Evaluation of IL-12 in Immunotherapy and Vaccine Design in Experimental 
*Mycobacterium avium* Infections

Regina A. Silva, Teresa F. Pais and Rui Appelberg

*J Immunol* 1998; 161:5578-5585; 
[http://www.jimmunol.org/content/161/10/5578](http://www.jimmunol.org/content/161/10/5578)

---

**Why The JI?**

- **Rapid Reviews! 30 days** from submission to initial decision
- **No Triage!** Every submission reviewed by practicing scientists
- **Speedy Publication!** 4 weeks from acceptance to publication

*average

**References**

This article *cites 38 articles*, 25 of which you can access for free at: [http://www.jimmunol.org/content/161/10/5578.full#ref-list-1](http://www.jimmunol.org/content/161/10/5578.full#ref-list-1)

**Subscription**

Information about subscribing to *The Journal of Immunology* is online at: [http://jimmunol.org/subscription](http://jimmunol.org/subscription)

**Permissions**

Submit copyright permission requests at: [http://www.aai.org/About/Publications/JI/copyright.html](http://www.aai.org/About/Publications/JI/copyright.html)

**Email Alerts**

Receive free email-alerts when new articles cite this article. Sign up at: [http://jimmunol.org/alerts](http://jimmunol.org/alerts)
Evaluation of IL-12 in Immunotherapy and Vaccine Design in Experimental Mycobacterium avium Infections

Regina A. Silva, Teresa F. Pais, and Rui Appelberg

IL-12 is a pivotal cytokine in the induction of IFN-γ-mediated protective immune responses. We tested the effects of rIL-12 administration to Mycobacterium avium-infected mice and found a limited ability to induce protection against the infection; this ability varied according to the mycobacterial strain studied. IL-12 accelerated the expression and production of IFN-γ in both immunocompetent and immunodeficient SCID or CD4-depleted mice. Evidence of NK cell activation was found as well as an enhancement of the ability to adoptively transfer resistance with T cell-enriched spleen cell populations and an increase in inflammatory cell recruitment in the liver. The protective ability of IL-12 was dependent upon the endogenous production of IFN-γ as evaluated by the use of specific neutralizing Abs or IFN-γ gene-disrupted mice. IL-12 potentiated the protective immunity conferred by a subunit vaccine containing M. avium culture filtrate proteins and dimethyl dioctadecyl ammonium chloride as an adjuvant. Thus, we show limited immunotherapeutic benefits from IL-12 administration in M. avium infections and promising results in its use as a coadjuvant in vaccine design. The Journal of Immunology, 1998, 161: 5578–5585.

M. avium is a facultative intracellular pathogen that frequently infects immunocompromised individuals. Several reports indicate that M. avium infection is one of the most common causes of systemic bacterial infection in AIDS patients in the United States and western Europe (24). Most AIDS patients develop disseminated M. avium infections when their circulating CD4+ T cell numbers are <100/mm³ (25), suggesting an important role for this T cell subset in the protective immune response against this pathogen. Disseminated M. avium infections have also been described in human patients deficient in the IFN-γR (26) in addition to those defective in IL-12 secretion or responsiveness to IL-12.

IL-12 is a cytokine with a major role in the induction of IFN-γ-dominated immune responses to microbial pathogens. Studies using neutralizing Abs or gene-disrupted animals have underscored the almost absolute requirement for IL-12 in the generation of protective Th1 immunity (1–9). Likewise, the exogenous administration of recombinant cytokine led to protection against different microbes (4, 6, 10–17), including mycobacteria (1, 18–20). In addition, other studies have described the adjuvanticity of IL-12 in vaccines against parasites such as Leishmania, where it increased protection (21), and Schistosoma, where it decreased pathology (22). On the other hand, the genetic basis of susceptibility to infection was related in some cases to defective IL-12 production (19). Human patients have also been identified that are particularly prone to mycobacterial infections due to defective IL-12 production or signaling (23).

Mycobacterium avium is a facultative intracellular pathogen that frequently infects immunocompromised individuals. Several reports indicate that M. avium infection is one of the most common causes of systemic bacterial infection in AIDS patients in the United States and western Europe (24). Most AIDS patients develop disseminated M. avium infections when their circulating CD4+ T cell numbers are <100/mm³ (25), suggesting an important role for this T cell subset in the protective immune response against this pathogen. Disseminated M. avium infections have also been described in human patients deficient in the IFN-γR (26) in addition to those defective in IL-12 secretion or responsiveness to IL-12.

Materials and Methods

Reagents, cytokines, and Abs

Mycobacterial growth media were purchased from Difco (Detroit, MI). RPMI 1640 cell culture medium and FCS were obtained from Life Technologies (Paisley, Scotland). Tween 80 and IFA were purchased from Sigma (St. Louis, MO). Anti-CD4 mAbs were obtained from the hybridoma GK1.5 (TIB 207 cell line; American Type Culture Collection [ATCC], Manassas, VA). The IFN-γ-neutralizing IgG1 was obtained from the hybridoma XMG1.2 (DNAX, Palo Alto, CA), and an irrelevant rat IgG1 against β-galactosidase was purified from hybridoma GL113 (DNAX). Hybridomas were grown in ascites in Harlan Sprague-Dawley nude mice primed with IFA. Abs were purified by affinity chromatography using a protein G-agarose column (Life Technologies). rIL-12 was a kind gift of the Genetics Institute (Cambridge, MA) and had a specific activity of 3.7 × 10⁶ U/mg.

Mice

Specific pathogen-free BALB/c female mice were purchased from the Gulbenkian Institute for Science (Oeiras, Portugal). Outbred Harlan Sprague-Dawley nude mice were purchased from the Gulbenkian Institute for Science and used to raise ascites from hybridomas. C.B-17 SCID female mice

1 This work was funded by Grants BIA247/94 and SAU58/96 from the PRAXIS programme (Lisbon, Portugal) and by National Institutes of Health contract AI-41922.

2 Address correspondence and reprint requests to Dr. Rui Appelberg, Laboratory of Microbiology and Immunology of Infection, Institute for Molecular and Cell Biology, University of Porto, Rua do Campo Alegre 823, 4150 Porto, Portugal. E-mail address: rappelb@ibmc.up.pt

3 Abbreviations used in this paper: rIL-12, murine rIL-12; PE, phycoerythrin; HPRT, hypoxanthine phosphoribosyltransferase; CFP, culture filtrate protein from M. avium; DDA, dimethyl dioctadecyl ammonium chloride.
were purchased from Bomninc (Ry, Denmark), and IFN-gamma gene-
disrupted (IFN-con) mice were generated by Dalton et al. (29). These
mice were kept in sterile housing conditions in cages provided with high-
efficiency particulate air filter-bearing caps. All mice were used at 6–8 wk
of age.

In some experiments, CD4+ T cell-depleted BALB/c mice were ob-
tained by thymectomy and anti-CD4 mAb administration as described
previously (27).

**Bacterial infections**

*M. avium* strains 25291 (from ATCC), 2447 (an AIDS isolate obtained
from Dr. F. Portaels, Institute of Tropical Medicine, Antwerp, Belgium),
and 1983 (a low virulence isolate from an HIV-negative patient) were
grown in Middlebrook 7H9 medium containing 0.04% Tween 80 at 37°C
until the mid-log phase of growth. Bacteria were harvested by centrifuga-
tion and resuspended in a small volume of saline containing 0.04% Tween
80. The suspension was briefly sonicated with a Branson sonicator (Danbury,
CT) for 15 s at 50 W to disrupt bacterial clumps, diluted, and frozen in
 aliquots at −70°C until use.

Mice were infected i.v. with 10⁶ CFU of *M. avium* 1983 or 10⁵ CFU of
*M. avium* 2447 or 25291 through a lateral tail vein. Mice were sacrificed by
cervical dislocation at different timepoints, and organs were collected, ho-
mogenized, serially diluted in a 0.04% Tween 80 solution in distilled water,
and plated onto Middlebrook 7H10 agar medium. The plates were incu-
bated for 2 wk at 37°C, and the number of CFU were counted. Data are
expressed as the log₁⁰ value of the mean number of CFU recovered per
organ ± SD of the mean (n = four or five animals). Differences were
analyzed by the Student's t test using unpaired data.

**Cytokine assays**

Serum was obtained from blood collected from sacrificed mice after al-
lowing clot formation at 37°C for 30 min followed by an incubation at 4°C
for 2 h to allow clot retraction. After centrifugation (10,000 rpm for 20 min
at 4°C), serum was collected and frozen at −70°C until use. IFN-γ levels
in individual sera were detected and quantified by a two-site sandwich
ELISA using anti-IFN-γ-specific affinity-purified mAbs (R4-6A2 as cap-
tive and biotinylated AN-18 as detecting) and a standard curve generated
with known amounts of rmIFN-γ (Genzyme, Cambridge, CA). The sensi-
tivity of the assay was 80 pg/ml.

**Treatment of mice with mAbs and cytokines**

To maintain CD4+ T cell depletion in thymectomized animals, 0.2 mg of
anti-CD4 mAb (GK.1.5) per animal was administered i.p. every 10 days
during the experimental infection. For IFN-γ neutralization, 2 mg of
XMGl.2 per animal was injected i.p. every 2 wk from the beginning of
infection. Control animals received the same amount of purified anti-
β-galactosidase mAb of the same isotype (GL113 mAb).

Treatment with rmIL-12 was performed by administrating 0.4 μg of this
cytokine per animal i.p. on every other day during 1 mo from the beginning
of the infection or during 3 wk starting on day 21 of infection.

**Adoptive transfer of spleen cells**

Spleens from BALB/c mice that had been infected for 3 or 6 wk with *M.
avium* strain 2447 or left uninfected and treated with rmIL-12 or left un-
treated were aseptically collected and gently teased in RPMI 1640 medium
containing 2% FCS (AT medium). Splenic cells were pooled (n = 4),
washed, and resuspended in hemolytic buffer (155 mM NH₄Cl, 10 mM
KHCO₃, pH 7.2) for 5–10 min at room temperature. After two washes in
AT medium, cells were resuspended in the same medium plus an equal
volume of J11d.2 (anti-CD24) and MK-D6 (anti-class II MHC) hybridoma
supernatants (total volume of 30 ml) and incubated with rabbit complement
in a 10-ml syringe barrel, and incubated for 2 h at 37°C. Nonadherent cells
were discarded, and cells were washed twice in AT medium. Cells were resus-
pended in AT medium, added to a nylon column containing 1.2 g of wool
and plated onto Middlebrook 7H10 agar medium. The plates were incu-
bated for 2 wk at 37°C, and the number of CFU were counted. Data are
expressed as the log₁⁰ value of the mean number of CFU recovered per
organ ± SD of the mean (n = four or five animals). Differences were
analyzed by the Student's t test using unpaired data.

**Flow cytometry**

Single-cell suspensions from the spleens of treated or control infected
SCID mice were prepared by teasing a portion of the spleen in medium.
For immunofluorescence double staining, 10⁶ cells were incubated in microtiter
plates for 20 min at 4°C with heat-inactivated rat serum. Cells were washed
and subsequently incubated for 30 min at 4°C with FITC-conjugated rat
anti-mouse CD90.2/Ty-1.2 (Becton Dickinson, Mountain View, CA) or rat anti-mouse CD11b/Mac1 and R-phycocyanin (PE)-conjugated ham-
ster anti-mouse CD3e mAbs (PharMingen, San Diego, CA). Cells were
washed twice with staining medium (PBS containing 3.1% sodium azide
and 5% FCS) and resuspended in staining medium containing propidium
iodide to identify and exclude dead cells. Flow cytometric analysis was
performed with a FACSort apparatus (Becton Dickinson) equipped with
Lysis II software by acquiring 10,000 events.

To analyze the T cell–enriched splenocytes from uninfected and infected
donor mice in the adoptive transfer experiments, 10⁶ cells from the T cell
pools were stained with PE-conjugated anti-mouse CD4 and FITC-conju-
gated anti-mouse CD8 (PharMingen) as described above.

**Histology**

Portions of the liver or spleen of infected mice were cut from the organs
with the aid of a sharp blade, fixed in buffered formaldehyde, and embed-
ed in paraffin. Next, 3-μm-thick sections were cut and stained for acid-
fast bacilli by the Ziehl-Neelsen method and either counterstained with
hematoxylin or stained with trichrome. Slides were analyzed for differ-
cences in the number and size of granuloma structures as well as for the
presence or absence of acid-fast rods. Representative fields were photo-
graphed with a Nikon microscope (Tokyo, Japan).

**RT-PCR**

Total RNA from spleen cell suspensions was isolated by guanidinium thiocya-
inate/phenol/chloroform purification and stored at −70°C until further
processing. Total mRNA was reverse transcribed using pdT12-18 oligo-
nucleotides (Pharmacia Biotech, Uppsala, Sweden) as primers and Super-
Script (Life Technologies) according to the manufacturer’s instructions.
The standardization for HPRT mRNA, the amplification products were run in a
1.5% agarose gel, transferred to nitrocellulose membranes (Hybond N+;
Amersham, Buckinghamshire, U.K.), and hybridized with specific probes
labeled with [α-32P]deoxyCTP. Membranes were exposed, and photo-
graphic plates were read with the aid of a computer-assisted scanner. Val-
ues for the PCR product for IFN-γ were corrected for the amount of HPRT
on each sample, taking into account the titration of both the HPRT and
IFN-γ cDNA from internal standards. All samples and the titrations were
run, blotted, and exposed in parallel to the same plates to ensure a correct
comparison of the signals generated. Data are expressed as the mean pixel
value of four or five samples from separate mice. Values were analyzed
using the Student’s t test.

**Vaccine preparation and immunization studies**

*M. avium* 2447 was generated for 2 wk in Sauton medium supplemented
with pyruvate and glucose; culture supernatants were obtained by centrifuga-
tion of the bacteria and filtration through 0.45-
㎛ filters. Such culture super-
natants were concentrated 100-fold through ultrafiltration using filters with
a molecular mass cutoff of 3 kDa. The resulting preparation was then sub-
jected to 80% ammonium sulfate precipitation followed by extensive di-
alysis against PBS. Therefore, this reagent was named culture filtrate pro-
tein from *M. avium* (CFP). To immunize animals, 45 μg of CFP was
injected three times s.c. at the base of the tail in separate locations, at
weekly intervals. CFP was administered as a solution or was admixed with
0.4 μg of rmIL-12 and/or 250 μg of dimethyl dioxetane ammonium
chloride (DDA) (Eastman Kodak, Rochester, NY) as adjuvants. The con-
trol mice received either PBS alone, rmIL-12 alone, DDA alone, or
rmIL-12 in DDA. At 1 mo after the last immunization, mice were chal-
lenged i.v. with 10⁶ CFU of *M. avium* strain 2447. The mycobacterial
loads in the spleen and liver were determined 30 days later as described above.

Flow cytometry
BALB/c mice were infected i.v. with $10^6$ CFU of either of two strains of $M. avium$.

Results

Evaluation of the effects of rmIL-12 administration during $M. avium$ infection

BALB/c mice were infected i.v. with $10^6$ CFU of either of two strains of $M. avium$ of distinct virulence (characterized in Ref. 31) and treated every other day with rmIL-12 (each dose containing 0.4 $\mu$g of IL-12/animal) or PBS i.p. during the first month of infection. The growth of $M. avium$ was studied in the spleen and liver of the infected animals for 60 days. The results showed that rmIL-12 induced statistically significant protection in the spleens of BALB/c mice infected with strains 25291 and 2447 but had no effect on the mycobacterial growth in the liver (Fig. 1A). The protection afforded in the spleen against the most virulent strain 25291 was minimal when compared with the overall growth of the mycobacteria, whereas a 0.9 $\log_{10}$ decrease in mycobacterial numbers was detected in the spleens of rmIL-12-treated mice infected with the low virulence strain 2447 but had no effect on the mycobacterial growth in the liver (Fig. 1A). The protection afforded in the spleen against the most virulent strain 25291 was minimal when compared with the overall growth of the mycobacteria, whereas a 0.9 $\log_{10}$ decrease in mycobacterial numbers was detected in the spleens of rmIL-12-treated mice infected with the low virulence strain 2447 but had no effect on the mycobacterial growth in the liver (Fig. 1A).

However, we could detect a 0.8 $\log_{10}$ difference in the splenic loads and a very minor although statistically significant decrease in hepatic loads of 0.3 $\log_{10}$ during infection by the low virulence strain 1983. Furthermore, we found killing of mycobacteria in the spleens of mice infected with this latter strain; this killing took place after the administration of the cytokine.

To understand the basis of the protective activity of rmIL-12 during the infection, we analyzed the expression of the protective cytokine IFN-\(\gamma\). Analysis was performed by RT-PCR of IFN-\(\gamma\) splenic expression in BALB/c mice treated i.p. with rmIL-12 (0.4 $\mu$g/animal every other day) or PBS and infected i.v. for 30 days with $10^6$ CFU of $M. avium$ strains 25291 and 2447. As shown in Fig. 2, treatment with rmIL-12 caused a minor increase in mRNA levels for IFN-\(\gamma\); however, this increase was not statistically significant. Since the timepoint chosen represents the peak of expression for IFN-\(\gamma\) during $M. avium$ infections (25, 31), and as the treatment with rmIL-12 might be accelerating its expression rather than increasing the peak expression of the cytokine, we selected strain 2447 and studied earlier timepoints of infection. Mice were infected as described, and half were treated with rmIL-12 as before. As shown in Fig. 3A, protection was induced by rmIL-12 therapy in both the spleen and liver and was already apparent on day 10 of infection. This early protection was associated with higher expression of IFN-\(\gamma\) mRNA on day 10 in rmIL-12-treated animals as compared with the controls (Fig. 3, B and C). However, such differences disappeared on day 20. The levels of immunoreactive IFN-\(\gamma\) present in the sera of the infected animals correlated well with the RT-PCR studies, in that rmIL-12 treatment induced high levels of IFN-\(\gamma\) on day 10 that decreased by day 20 of infection, such amounts of the cytokine always being higher in the rmIL-12-treated group as compared with the controls (Fig. 3D).
Evaluation of the effects of rmIL-12 treatment on T cell-independent immunity

The early enhanced production of IFN-γ could be due either to an acceleration of the T cell responses or to the boosting of innate immunity, namely of those mechanisms involving cells of the NK cell lineage. To evaluate the effects of rmIL-12 administration on T cell-independent immunity, SCID mice were infected i.v. with 10^6 CFU of *M. avium* strain 2447 for 1 mo; 0.4 mg of rmIL-12 was administered every other day from the beginning of the infection to one group of animals. Fig. 4A shows the mycobacterial load in the spleen and liver of the animals infected for 30 days. The administration of rmIL-12 potentiated the protective response in the spleens of SCID mice. However, the magnitude of the reduction in *M. avium* proliferation induced by rmIL-12 treatment was smaller than the one previously observed with immunocompetent BALB/c mice. The sera of rmIL-12-treated SCID mice had detectable levels of immunoreactive IFN-γ; IFN-γ was not detected in the control mice (Fig. 4B).

The rmIL-12-treated SCID mice showed a more extensive splenomegaly than control mice at 30 days of infection (data not shown). We characterized the spleen cell population at 30 days of infection by cytofluorometric analysis with anti-CD3 (PE) plus anti-CD90/Thy1.2 (FITC) or anti-CD11b/Mac1 (FITC) staining. A gate on CD3⁺Thy1.2⁻ or Mac1⁺ cells was used to characterize these populations in their complexity (side scatter). These studies showed that rmIL-12 induced an increase in the absolute number of Mac1⁺ cells but no increase in the Thy1.2⁺ population (Fig. 4C). This cytokine also induced an increase in the granularity of the CD3⁺Thy1.2⁺ and CD3⁺Mac1⁺ cell populations (Fig. 4, D and E, respectively), which suggests an activation of these cell populations.

Similar studies were performed on thymectomized BALB/c mice treated with anti-CD4 mAbs. Such mice, when given rmIL-12 in a protocol similar to that used in the SCID mice, showed reductions in splenic *M. avium* loads in two independent experiments of 0.3 and 0.7 log_{10} at day 15 and of 0.4 and 0.7 log_{10} at day 30 as compared with CD4-depleted mice that did not receive
the cytokine; this finding indicates that, in this model, the effects of rmIL-12 take place during the first 2 wk of treatment. Furthermore, at day 15 of infection, CD4-depleted mice had the same splenic mycobacterial loads as control thymectomized mice in either the cytokine-treated groups (5.22 ± 0.02 log$_{10}$ CFU vs 5.24 ± 0.08 log$_{10}$ CFU) or the groups that did not receive rmIL-12 (5.88 ± 0.02 log$_{10}$ CFU vs 5.99 ± 0.14 log$_{10}$ CFU), showing that the early protection at day 15 in this experiment was independent of CD4$^+$ T cells. Later on, however, the protection induced by IL-12 was higher in control compared with CD4-depleted animals. Thus, at day 30 of infection, the protection in the spleens of control mice was 1.1 log$_{10}$ whereas protection in CD4-depleted animals was 0.7 log$_{10}$.

**Evaluation of the effects of rmIL-12 treatment on T cell-dependent immunity**

To test the effects of the rmIL-12 treatment on the T cell populations, we studied the protective activity of T cell-enriched spleen cells from infected animals treated or untreated with the cytokine using a passive cell-transfer assay. A total of 16 donor mice were infected i.v. with 10$^6$ CFU of *M. avium* 2447 for 3 or 6 wk. Half of the animals were given rmIL-12 (0.4 μg/animal every other day for the entire period), and the other half were treated with PBS. Spleen cells from these immune animals as well as spleen cells from nonimmune controls were collected, enriched for T cells by depletion of Ia$^+$ cells and nylon wool-adherent cells, and infused into irradiated (500 rad) recipient animals. The latter were then challenged with 10$^6$ CFU of the same *M. avium* strain, and mycobacterial growth was evaluated 30 days later. We had already determined that the protection afforded by these cells can be abrogated by in vitro lysis of CD4$^+$ T cells by treatment with specific Abs and complement (data not shown). Fig. 5 shows that the injection of rmIL-12 in *M. avium*-infected donor mice accelerated the emergence of a population of T cells that were able to adoptively transfer protection to sublethally irradiated recipient mice.

**Study of the protective mechanisms induced by rmIL-12 administration**

To test whether the protective effect of rmIL-12 in immunocompetent animals was dependent upon IFN-γ, we compared the effects of rmIL-12 treatment on the growth of *M. avium* in BALB/c mice given neutralizing Abs vs respective controls or in IFN-γ gene-disrupted animals (IFN-γ$^{-/-}$) and normal heterozygous controls (IFN-γ$^{+/-}$). Mice were infected i.v. with 10$^6$ CFU of *M. avium* 2447 for 1 mo and treated every other day with either PBS or 0.4 μg of rmIL-12/animal. Fig. 6 shows the mycobacterial loads in spleens and livers of mice infected for 30 days. The protective effects of rmIL-12 in the spleen were dependent upon the endogenous production of IFN-γ. Such effects were particularly evident with the IFN-γ$^{-/-}$ mice, but similar results were obtained when immunocompetent BALB/c mice were used and specific neutralizing Abs were given to deplete IFN-γ. Fig. 7 shows the histologic analysis of the livers of these animals. Untreated IFN-γ$^{-/-}$ mice had a marked decrease in granuloma formation during infection as compared with control heterozygous mice. Treatment of mice with rmIL-12 increased granuloma formation both in control and IFN-γ-deficient animals. Analysis of the spleens showed invasion of the white pulp by macrophages during infection. Although granulomas were less easily discernible within the lymphoid mass, their number was enhanced by the infusion of rmIL-12 in both immunocompetent and IFN-γ$^{-/-}$ mice (data not shown).

**Adjuvactivity of rmIL-12 in a subunit M. avium vaccine preparation**

To evaluate the possible usefulness of IL-12 in the design of antimycobacterial vaccines, we selected secreted proteins from *M.
avium as the Ag source. This choice was based on the previous work of several groups that described the effective use of such preparations in the induction of protective immunity against Mycobacterium tuberculosis (32). CFPs were injected either alone or in combination with DDA as an adjuvant (33). rmIL-12 was administered together with CFP or CFP plus DDA to subgroups of animals. Controls for the nonspecific, inflammatory-dependent induction of resistance to infection included the administration of rmIL-12 and DDA, both alone or in combination, as well as the vehicle, PBS. We chose to administer the cytokine with every dose of the vaccine, since preliminary results showed no benefit of a single dose during the first immunization (Ref. 33 and our unpublished observations). As shown in Fig. 8, significant resistance was conferred by the adjuvants alone in this experiment when the challenge took place 1 mo after the last immunization. This was particularly evident in the liver. However, all three preparations containing the Ag, CFP, admixed with DDA, rmIL-12, or both conferred significantly higher protection in the liver than any of the other preparations lacking Ag or the CFP treatment alone, without any adjuvant. In the spleen, in contrast, high levels of protection \( (p < 0.01 \text{ toward all other groups}) \) leading to 10-fold lower numbers of mycobacteria were only obtained when CFP was administered in combination with both DDA and rmIL-12.

**Discussion**

We describe here our assessment of the usefulness of rIL-12 as an immunotherapeutic drug against *M. avium* infections as well as its role as an adjuvant in a subunit vaccine against that pathogen. We used therapeutic regimens that are similar to those used by other researchers and that resulted in beneficial effects without the toxic ones associated with higher doses of IL-12 administration. We found that rIL-12 afforded significant but very limited protection in the spleens of mice infected with either of two strains of *M. avium* of low virulence. Alternatively, the growth of *M. avium* in another target organ, the liver, was not consistently affected by treatment. Also, protection was predominantly afforded by early rather than delayed treatment as tested with one of the strains. However, no valuable protective effects were found during the treatment of an infection by a highly virulent strain of *M. avium*. These results are in tune with our findings and those of others that those latter virulent strains resist the antimycobacterial activity of IFN-\( \gamma \)-activated macrophages (Refs. 34 and 35 and our unpublished observations). Therefore, further activation of those pathways is without success in the control of such infections. The effects of rIL-12 administration to mice infected with *M. avium* have already been studied by Kobayashi et al. (19). They found that IL-12 administered in a regimen very similar to the one used here for strain 1983

**FIGURE 7.** Histologic sections of infected livers of IFN-\( \gamma \)^-/- (A and B) and IFN-\( \gamma \)^+/- (C and D) mice treated with PBS (A and C) or rmIL-12 (B and D) after 30 days of infection. Note the paucity of inflammatory foci in untreated IFN-\( \gamma \)^-/- mice and the increase in inflammatory cell recruitment in both strains of mice after IL-12 treatment. The photomicrographs represent typical views of the livers of groups of four animals.

**FIGURE 8.** Protection afforded by the CFP-based vaccine admixed with either DDA, rmIL-12, or both as well as the respective controls. Mice were injected s.c. three times at weekly intervals with the preparations shown. Animals were challenged i.v. with *M. avium* 2447 at 1 mo after the last immunization, and mycobacterial loads were evaluated 30 days later. Results are shown as log\(_{10}\) protection, which was calculated by subtracting the mean log\(_{10}\) CFU in the treated group from the mean log\(_{10}\) CFU in PBS-treated controls. Therefore, negative values represent exacerbation of the infection by the treatment. In the liver, the three preparations, which contained the Ag (CFP) admixed with either of two strains of *M. avium* of low virulence. Alternatively, the growth of *M. avium* in another target organ, the liver, was not consistently affected by treatment. Also, protection was predominantly afforded by early rather than delayed treatment as tested with one of the strains. However, no valuable protective effects were found during the treatment of an infection by a highly virulent strain of *M. avium*. These results are in tune with our findings and those of others that those latter virulent strains resist the antimycobacterial activity of IFN-\( \gamma \)-activated macrophages (Refs. 34 and 35 and our unpublished observations). Therefore, further activation of those pathways is without success in the control of such infections. The effects of rIL-12 administration to mice infected with *M. avium* have already been studied by Kobayashi et al. (19). They found that IL-12 administered in a regimen very similar to the one used here for strain 1983

**FIGURE 8.** Protection afforded by the CFP-based vaccine admixed with either DDA, rmIL-12, or both as well as the respective controls. Mice were injected s.c. three times at weekly intervals with the preparations shown. Animals were challenged i.v. with *M. avium* 2447 at 1 mo after the last immunization, and mycobacterial loads were evaluated 30 days later. Results are shown as log\(_{10}\) protection, which was calculated by subtracting the mean log\(_{10}\) CFU in the treated group from the mean log\(_{10}\) CFU in PBS-treated controls. Therefore, negative values represent exacerbation of the infection by the treatment. In the liver, the three preparations, which contained the Ag (CFP) admixed with DDA \( (p < 0.05 \text{ against DDA plus IL-12 and } p < 0.01 \text{ against all other groups not containing CFP or against CFP alone}) \), rmIL-12 \( (p < 0.05 \text{ against DDA plus IL-12 and } p < 0.01 \text{ against all other groups not containing CFP or against CFP alone}) \), or both \( (p < 0.01 \text{ against all groups not containing CFP or against CFP alone}) \), gave statistically significant higher protection. In the spleen, higher levels of protection were found when CFP was administered in combination with both DDA and rmIL-12 \( (p < 0.01 \text{ vs all other groups}) \).
(a strain chosen to have a virulence similar to that of the strain used in their study (36)) led to a killing of the mycobacteria in the spleens of infected animals. We corroborate their observations, but stress that the efficacy of the IL-12 treatment is clearly dependent on the characteristics of the particular strain of M. avium studied. This information may turn out to be of importance if IL-12 is considered for human immunotherapy. We found no clinically apparent toxic effects of prolonged IL-12 therapy, but histologic analysis of the infected livers showed a marked increase in the granulomatous response. This enhancement was partially independent of the infection itself, since we observed marked cellular infiltration and granuloma formation in the livers of uninfected mice treated with similar regimens of rmIL-12 (our unpublished observations). Part of the toxicity of IL-12 was reported to be dependent upon the triggering of TNF-α production (37). Since TNF-α is also involved in resistance to M. avium infection (27), the neutralization of this cytokine during IL-12 therapy to decrease the toxicity of therapy would not be warranted. The limited effects of rmIL-12 therapy on the overall growth or killing of mycobacteria have also been documented for other mycobacterial species. In one report, the protection afforded by rmIL-12 against a tuberculous challenge in BALB/c mice was also limited to one log10; however, in that model, such improvement of the control of the infection prolonged the survival of the mice (20). Cooper et al. (1, 18) have also described low levels of protection in an i.v. challenge model of murine tuberculosis. Here, we found that the less virulent the strain of M. avium, the bigger the protection conferred by rmIL-12 therapy. Finally, a recent report that appeared after our initial submission of this work shows similar levels of protection after IL-12 therapy of SCID mice infected with M. avium (38). In that study, IL-12 was shown to potentiate the efficacy of chemotherapy.

We used strain 2447 to dissect the basis of the protective effect afforded by IL-12. Such protection was dependent both on the induction of innate mechanisms involving the activation of macrophages and NK cells and on the acceleration of the T cell response. Both cell types were responsible for the enhanced early production of IFN-γ that was required for the decrease in mycobacterial proliferation. This was shown using SCID mice or CD4-depleted mice to evidence the innate immunity mechanisms and by performing an adoptive transfer of protection to highlight the role of T cells. Also, the protective effects of IL-12 therapy were higher in immunocompetent than in T cell-deficient animals and were only expressed against strain 2447 when the cytokine was given at a time when T cell-mediated immunity was emerging, rather than when it was already present (i.e., at wk 3 of infection) (Fig. 1, A vs B). However, the relative importance of either of the protective mechanisms triggered by IL-12 in an immunocompetent mouse was not clear.

In accordance with other studies (20), we found that the protective effect of IL-12 was dependent upon the endogenous production of IFN-γ and was associated with an increased development of granulomatous inflammation in the liver. In the absence of IFN-γ, IL-12 was also able to increase the recruitment of inflammatory cells despite its inability to protect from infection. A similar dependence of the effects of IL-12 on the endogenous production of IFN-γ has also been found in other infectious models (10–12, 14, 16, 17).

More promising to our point of view than the immunotherapeutic potential of rmIL-12 were the findings of the potentiation of the protective immune responses elicited by CFPs by IL-12 coadministration. Although the results are clearly preliminary and more extensive studies should be performed to assess the longevity of the protective immunity generated, it is interesting to note that protection of one log10 or more was found in both the target organs studied only when rmIL-12 was included in the vaccine. It will be important to subject the animals to a more prolonged resting period between immunization and challenge to eliminate the nonspecific protection induced by preparations devoid of Ag, which were studied here to control for the specificity of the vaccine. The limited albeit significant protection afforded by the adjuvant preparations alone in this experiment was most likely due to the accumulation of inflammatory cells at the sites of infection induced by the presence of the adjuvants given only 1 mo before the infection. These cells may be producing cytokines that play a modest protective role on the subsequent infection. Nevertheless, despite the existence of such nonspecific protection, the Ag-specific protection was clearly above the former; most of all, it could only be found in the spleen if rmIL-12 was included in the vaccine. It was curious to note that although the protection afforded by immunotherapy during infection was particularly evident in the spleen, the adjuvant effects of IL-12 were more marked in the liver of the animals. The superiority of the immunotherapy in the spleen can be explained by the later emergence of protection in this organ during infection as compared with the liver. Therefore, treatment with rmIL-12 accelerates protective mechanisms, so that protection appears sooner in the spleen, while protection in the liver may not be further accelerated. This easier recruitment of T cell-mediated protection to the liver as compared with the spleen can also be seen with the vaccinated animals where suboptimal regimens (CFP with only one of the adjuvants) were already effective, whereas the combination of the three components of the vaccine was necessary to boost the protective efficacy of the immunization to act in the spleen.

In summary, we illustrate the variable protection afforded by immunotherapy with rmIL-12 in murine models of M. avium infection; this protection depended upon the virulence of the mycobacterial strains being tested. The protection was dependent upon the endogenous production of IFN-γ produced by cells from the NK cell lineage or from protective T cells that emerged more rapidly when the cytokine was provided exogenously. The inability to boost the peak of maximum IFN-γ response was probably the reason for the limited protection afforded by the cytokine. However, the use of rmIL-12 as a coadjuvant in vaccine preparations was a most promising one.

Acknowledgements

We thank S. Wolf and the Genetics Institute for supplying murine rIL-12.

References

15. Khan, I. A., T. Matsuura, and L. H. Kasper. 1994. Interleukin-12 enhances mu-
23. Drysdale, P., D. A. Lammas, K. Quibell, D. S. Kumararatne, D. Schoell-Tollner,
22. Wynn, T. A., A. W. Cheever, D. Jankovic, R. W. Poindexter, P. Caspar,
12. Murray, H. W., and J. Hariprashad. 1995. Interleukin 12 is effective treatment for
15. Khan, I. A., T. Matsuura, and L. H. Kasper. 1994. Interleukin-12 enhances mu-
12. Murray, H. W., and J. Hariprashad. 1995. Interleukin 12 is effective treatment for